tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 May;19(5):e70115.
doi: 10.1111/irv.70115. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance
Annika Erdwiens[SUP] 1 [/SUP], Carolin Hackmann[SUP] 1 [/SUP], Marianne Wedde[SUP] 2 [/SUP], Barbara Biere[SUP] 2 [/SUP], Janine Reiche[SUP] 2 [/SUP], Ute Preuß[SUP] 1 [/SUP], Kristin Tolksdorf[SUP] 1 [/SUP], Silke Buda[SUP] 1 [/SUP], Ralf Dürrwald[SUP] 2 [/SUP]
Affiliations
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.
Keywords: hospitalization; influenza; primary care; vaccine; vaccine effectiveness.
. 2025 May;19(5):e70115.
doi: 10.1111/irv.70115. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance
Annika Erdwiens[SUP] 1 [/SUP], Carolin Hackmann[SUP] 1 [/SUP], Marianne Wedde[SUP] 2 [/SUP], Barbara Biere[SUP] 2 [/SUP], Janine Reiche[SUP] 2 [/SUP], Ute Preuß[SUP] 1 [/SUP], Kristin Tolksdorf[SUP] 1 [/SUP], Silke Buda[SUP] 1 [/SUP], Ralf Dürrwald[SUP] 2 [/SUP]
Affiliations
- PMID: 40328669
- PMCID: PMC12055342
- DOI: 10.1111/irv.70115
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.
Keywords: hospitalization; influenza; primary care; vaccine; vaccine effectiveness.